pgn-edo51
pgn-edo51: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| PepGen Inc. (PEPG) | Phase 2 |
Clinical Trials (1)
A Phase 2, Open-Label, Multiple Ascending Dose Study of PGN-EDO51 With a Long-Term Extension in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (CONNECT1-EDO51)
Frequently asked questions
Who is developing pgn-edo51?
pgn-edo51 is being developed by PepGen Inc..
How many clinical trials involve pgn-edo51?
BioSniper tracks 1 clinical trial involving pgn-edo51.
Get deeper analysis on pgn-edo51
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis